Agios Pharmaceuticals (AGIO) Profit After Tax (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Profit After Tax data on file, last reported at -$100.7 million in Q2 2026.

• Quarterly Profit After Tax rose 10.1% year-over-year to -$100.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$411.3 million (down 163.27% YoY) and the FY2025 annual result came in at -$412.8 million, down 161.27% from the prior year.
• Profit After Tax eased to -$100.7 million in Q2 2026, from -$99.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $947.9 million in Q3 2024 to a low of -$112.0 million in Q2 2025.
• A 5-year average of -$29.0 million and a median of -$93.3 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 362.66% — and 2024, when it jumped 1137.97%.
• Tracing AGIO's Profit After Tax over 5 years: stood at $36.5 million in 2022, then plunged by 362.66% to -$95.9 million in 2023, then retreated by 0.61% to -$96.5 million in 2024, then dropped by 11.93% to -$108.0 million in 2025, then increased by 6.79% to -$100.7 million in 2026.
• The last three Profit After Tax figures came in at -$100.7 million (Q2 2026), -$99.1 million (Q1 2026), and -$108.0 million (Q4 2025), per Business Quant data.